Supporting Information

Introverted Brønsted Acid Cavitands

for Selective Conjugate Addition Reactions

Yasuhiro Matsumoto, Yuta Taguchi, Naruhiro Yoshida, Shugo Tokai, Tomoyuki Maruyama,

and Tetsuo Iwasawa*

Dedicated to Professor François Diederich who sadly passed away on the 23rd of

September 2020.

Department of Materials Chemistry, Ryukoku University, Seta, Otsu, 520-2194, Japan

Contents

- **1.** Portions of NMR spectra of $1 \cdot C_5 H_5 N$ (Figure 1S).
- ¹H NMR spectra of 1·(2-vinyl)pyridine, 2·(2-vinyl)pyridine, 3·(2-vinyl)pyridine, 4·(2-vinyl)pyridine. (Figure 2S (a)-(d)).
- ¹H NMR and ¹³C NMR and ³¹P NMR spectra for all new compounds of 1•C₅H₅N, 1,
 2•C₅H₅N, 2, 3•C₅H₅N, 3, 4•C₅H₅N, 4, 5, 6, and 7.
- **4.** HRMS (ESI) data for the $1 \cdot C_5 H_5 N$ complex.

1. Portions of NMR spectra of $1 \cdot C_5 H_5 N$ (Figure 1S).



Figure 1S. Portions of the spectra of $1 \cdot C_5H_5N$ for (a) ¹H NMR (400 MHz, CD₂Cl₂, 298 K) from 3.8 to 5.9 ppm, and (b) ¹³C NMR (100 MHz, CD₂Cl₂, 298 K) from 122.1 to 125.2 ppm and from 134.8 to 140.4 ppm. •: The broad peaks of 5.58, 4.70, and 4.14 ppm correspond to 2-, 4-, and 3-positioned protons of an interior pyridine with properly integral values of 2 : 1 : 2, respectively; •: Three kinds of carbon peaks in an encapsulated pyridine located at 139.9, 138.9, 124.1 ppm for 2-, 4-, 3-positioned carbons, respectively.

¹H NMR spectra of 1•(2-vinyl)pyridine, 2•(2-vinyl)pyridine, 3•(2-vinyl)pyridine, 4•(2-vinyl)pyridine. (Figure 2S (a)-(d)).

Compound 1 • (2-vinyl) pyridine (¹H NMR spectrum in CDCl₃)



Figure 2S (a). ¹H NMR (400 MHz, CDCl₃) spectrum of **1**·(2-vinyl)pyridine: 8.27 (s, 2H), 7.94 (m, 2H), 7.75 (m, 2H), 7.61 (m, 2H), 7.49 (m, 4H), 7.32 (m, 4H), 7.29 (s, 2H), 7.23 (s, 2H), 6.23 (brs, 1H, C<u>H</u>₂=CH-), 5.73 (t, *J* = 8.0 Hz, 1H), 5.60 (t, *J* = 8.0 Hz, 2H), 5.22 (brs, 1H, C<u>H</u>₂=CH-), 4.92 (brs, 1H) 2.36-2.26 (m, 8H), 1.45-1.28 (m, 72H), 0.90-0.87 (m, 12H) ppm.





Figure 2S (b). ¹H NMR (400 MHz, CDCl₃) spectrum of **2**•(2-vinyl)pyridine: 8.41 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.66 (d, J = 8.1 Hz, 1H), 7.55-7.48 (m, 4H, including one proton of the pyridine ring), 7.35 (s, 1H), 7.33 (s, 1H), 7.20 (m, 2H), 7.18 (s, 1H), 7.13 (s, 1H), 7.00 (brs, 1H, CH₂=C<u>H</u>-), 6.47 (s, 1H), 5.90 (brs, 1H, C<u>H</u>₂=CH-), 5.73 (t, J = 8.0 Hz, 1H), 5.70 (t, J = 8.0 Hz, 1H), 5.52 (d, J = 7.2 Hz, 1H, -O-C<u>H</u>₂-O-), 5.21 (brs, 1H, C<u>H</u>₂=CH-), 4.79 (t, J = 8.0 Hz, 1H), 4.69 (t, J = 8.0 Hz, 1H), 4.10 (d, J = 7.2 Hz, 1H, -O-C<u>H</u>₂-O-), 2.29-2.22 (m, 8H), 1.45-1.27 (m, 72H), 0.90-0.87 (m, 12H) ppm. Compound **3**•(2-vinyl)pyridine (¹H NMR spectrum in CDCl₃)



Figure 2S (c). ¹H NMR (400 MHz, CDCl₃) spectrum of **3**•(2-vinyl)pyridine: 8.25 (brs, 1H, 6-positioned proton of pyridine ring), 7.89 (brs, 1H, 3-positioned proton of the pyridine ring), 7.77 (d, J = 7.8 Hz, 2H), 7.72 (d, J = 7.8 Hz, 2H), 7.52-7.44 (m, 5H, including 4-positioned proton of the pyridine ring), 7.39 (s, 2H), 7.33 (s, 2H), 7.22 (s, 2H), 7.19 (s, 2H), 7.13 (brs, 1H, 5-positioned proton of the pyridine ring), 6.90 (dd, J = 17.2, 12.4 Hz, 1H, CH₂=CH-), 6.25 (d, J = 17.2 Hz, 1H, CH₂=CH-), 5.80-5.65 (br, 1H, CH₂=CH-), 5.75 (d, J = 7.4 Hz, 1H, -O-CH₂-O-), 5.69 (t, J = 8.2 Hz, 2H), 4.84 (t, J = 8.2 Hz, 1H), 4.73 (t, J = 8.2 Hz, 1H), 4.26 (d, J = 7.4 Hz, 1H, -O-CH₂-O-), 2.27 (m, 8H), 1.44-1.27 (m, 72H),

0.91-0.86 (m, 12H) ppm.



Compound **4**•(2-vinyl)pyridine (¹H NMR spectrum in CDCl₃)

Figure 2S (d). ¹H NMR (400 MHz, CDCl₃) spectrum of **4**·(2-vinyl)pyridine: 8.69 (d, J = 5.7 Hz, 1H, 6-positioned proton of the pyridine ring), 8.16 (dd, J = 7.8, 7.8 Hz, 1H, 4-positioned proton of the pyridine ring), 7.95 (d, J = 7.8 Hz, 1H, 3-positioned proton of the pyridine ring), 7.91 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.64-7.54 (m, 3H, including 5-positioned proton of the pyridine ring), 7.46 (s, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 7.15 (s, 1H), 7.12 (s, 1H), 7.10 (s, 1H), 7.09 (dd, J = 14.6, 11.2 Hz, 1H, CH₂=C<u>H</u>-), 6.56 (s, 1H), 6.43 (d, J = 14.6 Hz, 1H, C<u>H</u>₂=CH-), 6.42 (s, 1H), 5.85 (d, J = 11.2 Hz, 1H, C<u>H</u>₂=CH-), 5.76 (t, J = 7.8 Hz, 1H), 5.72 (d, J = 7.2 Hz, 1H, -O-C<u>H</u>₂-O-), 5.52 (d, J = 7.2 Hz, 1H, -O-C<u>H</u>₂-O-), 4.78 (t, J = 7.8 Hz, 1H), 4.69 (t, J = 7.8 Hz, 2H), 4.45 (d, J = 7.2

Hz, 1H, -O-C<u>H</u>₂-O-), 4.44 (d, *J* = 7.2 Hz, 1H, -O-C<u>H</u>₂-O-), 2.32-2.21 (m, 8H), 1.47-1.27 (m, 72H), 0.89-0.86 (m, 12H) ppm.

3. ¹H NMR and ¹³C NMR and ³¹P NMR spectra for all new compounds of $1 \cdot C_5 H_5 N$, 1,

 $2 \cdot C_5 H_5 N$, 2, $3 \cdot C_5 H_5 N$, 3, $4 \cdot C_5 H_5 N$, 4, 5, 6, and 7.

Compound 1 • C₅H₅N (¹H NMR spectrum in CD₂Cl₂)







Compound $1 \cdot C_5 H_5 N$ (¹³C NMR spectrum in CD₂Cl₂)







Compound free acid **1** (¹H NMR spectrum in CDCl₃)





Compound free acid 1 (³¹P NMR spectrum in CDCl₃)



Compound $2 \cdot C_5 H_5 N$ (¹H NMR spectrum in CD₂Cl₂)











Compound free acid 2 (³¹P NMR spectrum in CD₂Cl₂)



Compound 3•C₅H₅N (¹H NMR spectrum in CD₂Cl₂)





Compound 3-C₅H₅N (³¹P NMR spectrum in CD₂Cl₂)









Compound $4 \cdot C_5 H_5 N$ (¹H NMR spectrum in CDCl₃)











Compound free acid 4 (³¹P NMR spectrum in CDCl₃)













Compound 7 (1H NMR spectrum in CDCl₃)







4. HRMS (ESI) data of $1 \cdot C_5 H_5 N$.

